Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy

Alexandre Hirayama • 2 Jul 2019
ICML 2019
Hodgkin Lymphoma Lymphoma Antibodies Camidanlumab tesirine

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the analysis of the clinical determinants for the safety and effiacy of camidanlumab tesirine (Cami-T; ADCT-301) for relapsed/refractory classical Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Alexandre Hirayama

1:31
Recent publication on the impact of response to lymphodepletion on PFS in NHL
Alexandre Hirayama • 20 Jun 2019
0:47
Durable responses after CD19 CAR-T plus ibrutinib in CLL
Alexandre Hirayama • 20 Jun 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals